Skip to content
value.today

Auspex Pharmaceuticals, Inc.

🇺🇸 Vista, California, USAPharmaceuticalsFounded 2007
Total raised
$65 M
8 rounds on record
Latest round
$28 M
Oct 2012
First round on record
Jun 2007
Today
Private
No later event on record

Funding rounds

8 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Auspex Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2012$28 MNo. 8$10 to $50 million

Auspex Pharmaceuticals, Inc.: Raise no. 8, Oct 2012

Investors in this round

9 investors had bought by the notice of Sep 6, 2013: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $28 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andreas Sommer · Executive Officer
  • David. A. Stamler · Executive Officer
  • Pratik A. Shah · Executive Officer, Director
  • David Collier · Director
  • Rod A. Ferguson · Director
  • Samuel Saks · Director
  • Sep Sarshar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andreas Sommer, PhD, President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Sep 6, 2013. Read the notice at the SEC.

equitySEC
Jul 2012$2 MNo. 7Under $2 million

Auspex Pharmaceuticals, Inc.: Raise no. 7, Jul 2012

Investors in this round

5 investors had bought by the notice of Jul 31, 2012: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andreas C. Sommer · Executive Officer
  • David C. Stamler · Executive Officer
  • Lawrence C. Fritz · Executive Officer, Director
  • David C. Collier · Director
  • Pratik C. Shah · Director
  • Samuel C. Saks · Director
  • Sep C. Sharshar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Warrants for the purchase of Preferred Stock were issued in connection with the Offering for no additional consideration. The aggregate number of warrant shares is contingent on a formula set forth in each of the warrants.”

Signed by Lawrence C. Fritz, President & CEO. Source: SEC Form D, newest notice filed Jul 31, 2012. Read the notice at the SEC.

debt, optionsSEC
Dec 2011$3 MNo. 6$2 to $10 million

Auspex Pharmaceuticals, Inc.: Raise no. 6, Dec 2011

Investors in this round

7 investors had bought by the notice of Jan 11, 2012: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $6 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andreas A. Sommer · Executive Officer
  • David A. Stamler · Executive Officer
  • Lawrence C. Fritz · Executive Officer, Director
  • David Collier · Director
  • Pratik Shah · Director
  • Samuel Saks · Director
  • Sepehr Sarshar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Warrants for the purchase of Pref Stock were issued at the Offering. No additional consideration was received for the Warrants. The # of warrant shares issuable upon exercise of the Warrants is contingent upon a formula set forth in each of the Warrants.”

Signed by Lawrence C. Frtiz, President and CEO. Source: SEC Form D, newest notice filed Jan 11, 2012. Read the notice at the SEC.

debt, optionsSEC
Jul 2010$12 MNo. 5$10 to $50 million

Auspex Pharmaceuticals, Inc.: Raise no. 5, Jul 2010

Investors in this round

8 investors had bought by the notice of Jul 16, 2010: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andreas Gary Sommer · Executive Officer
  • Pratik Shah · Executive Officer, Director
  • R. Gary Gilmore · Executive Officer
  • Samuel Saks · Executive Officer, Director
  • David Collier · Director
  • Sepehr Sarshar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Jul 16, 2010. Read the notice at the SEC.

equitySEC
Jan 2010$2 MNo. 4$2 to $10 million

Auspex Pharmaceuticals, Inc.: Raise no. 4, Jan 2010

Investors in this round

6 investors had bought by the notice of Feb 26, 2010: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andreas Gary Sommer · Executive Officer
  • Pratik Shah · Executive Officer, Director
  • R. Gary Gilmore · Executive Officer
  • Ron Gary Newbold · Executive Officer
  • David Collier · Director
  • Samuel Saks · Director
  • Sep Sarshar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “No additional consideration was received for the issuance of the warrants. The aggregate number of warrant shares issuable upon exercise of the warrants is contingent upon a formula set forth in each of the warrants.”

Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Feb 26, 2010. Read the notice at the SEC.

debt, optionsSEC
Oct 2009$2 MNo. 3$2 to $10 million

Auspex Pharmaceuticals, Inc.: Raise no. 3, Oct 2009

Investors in this round

5 investors had bought by the notice of Oct 22, 2009: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andreas Gary Sommers · Executive Officer
  • Pratik Shah · Executive Officer, Director
  • R. Gary Gilmore · Executive Officer
  • Ron Gary Newbold · Executive Officer
  • David Collier · Director
  • Sam Sachs · Director
  • Sep Sarshar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “No additional consideration was received for the issuance of the warrants. The aggregate number of warrant shares issuable upon exercise of the warrants is contingent upon a formula set forth in each of the warrants.”

Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Oct 22, 2009. Read the notice at the SEC.

debt, optionsSEC
May 2009$3 MNo. 2$2 to $10 million

Auspex Pharmaceuticals, Inc.: Raise no. 2, May 2009

Investors in this round

7 investors had bought by the notice of Aug 3, 2009: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, other: Promissory Notes convertible into Preferred Stock and Warrants to purchase shares of Preferred Stock were issued in connection with the Offering.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Grey · Executive Officer, Director
  • R. Gary Gilmore · Executive Officer
  • Sep Sarshar · Executive Officer, Director
  • Thomas Gant · Executive Officer, Director
  • David Collier · Director
  • Pratik Shah · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Aug 3, 2009. Read the notice at the SEC.

debt, optionsSEC
Jun 2007$14 MNo. 1$10 to $50 million

Auspex Pharmaceuticals, Inc.: Raise no. 1, Jun 2007

Investors in this round

5 investors had bought by the notice of Jul 30, 2010: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Auspex Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andreas Gary Sommer · Executive Officer
  • Pratik Shah · Executive Officer, Director
  • R. Gary Gilmore · Executive Officer
  • Samuel Saks · Executive Officer, Director
  • David Collier · Director
  • Sepehr Sarshar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by R. Gary Gilmore, CFO and Secretary. Source: SEC Form D, newest notice filed Jul 30, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Auspex Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2013).

    SEC Form D · Sep 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2013

That is all the official record says: Auspex Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Auspex Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
CMEA Ventures VII LPVenture capitalnot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Cmea Ventures VII (parallel) LPVenture capitalnot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Private Design Fund II, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Private Design International II, Ltd.Companynot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Deerfield Special Situations International Master Fund, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Panorama Capital, L.P.Fund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Sepehr SarsharPersonnot statednot statedHeld Series A-1, A-2, A-3, A-4, A-5, B, C and D preferred (Form 3, 2014)SEC Form 3
Thomas, McNerney & Partners II, LLCFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner, director (Form 3, 2014)SEC Form 3
Thomas, McNerney & Partners II L.P.Fund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TMP Associates II LPFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TMP Nominee II, LLCOthernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Auspex Pharmaceuticals, Inc.
NameRoleNamed in
Andreas SommerExecutive officerSep 2013
David. A. StamlerExecutive officerSep 2013
Pratik A. ShahExecutive officerSep 2013
Andreas C. SommerExecutive officerNov 2012
Lawrence C. FritzExecutive officerNov 2012
David C. StamlerExecutive officerJul 2012
Andreas A. SommerExecutive officerJan 2012
David A. StamlerExecutive officerJan 2012
Andreas Gary SommerExecutive officerJul 2010
Pratik ShahExecutive officerJul 2010
R. Gary GilmoreExecutive officerJul 2010
Samuel SaksExecutive officerJul 2010
Ron Gary NewboldExecutive officerFeb 2010
Andreas Gary SommersExecutive officerOct 2009
Michael GreyExecutive officerAug 2009
Sep SarsharExecutive officerAug 2009
Thomas GantExecutive officerAug 2009
David CollierDirectorSep 2013
Pratik A. ShahDirectorSep 2013
Rod A. FergusonDirectorSep 2013
Samuel SaksDirectorSep 2013
Sep SarsharDirectorSep 2013
David C. CollierDirectorNov 2012
Gaurav A. AggarwalDirectorNov 2012
Lawrence C. FritzDirectorNov 2012
Samuel C. SaksDirectorNov 2012
Sep C. SarsharDirectorNov 2012
Pratik C. ShahDirectorJul 2012
Sep C. SharsharDirectorJul 2012
Pratik ShahDirectorJan 2012
Sepehr SarsharDirectorJan 2012
Sam SachsDirectorOct 2009
Michael GreyDirectorAug 2009
Thomas GantDirectorAug 2009